Date: 2014-02-06
Type of information: Private placement
Company: Mologen (Germany)
Investors:
Amount: €15.7 million
Funding type: private placement
Planned used: The proceeds from the capital increase will be used to further strengthen the equity base as well as to finance the development of the product pipeline and the proceeds enable in particular to start the planned pivotal clinical phase III study with MGN1703 in metastatic colorectal cancer. Mologen has also applied for a randomized, controlled clinical study to evaluate the efficacy of MGN1703 in lung cancer, which is scheduled to begin in the first half of 2014.
Others: * On February 6, 2014, Mologen has announced it has successfully concluded its capital increase. In the context of a private placement the capital increase was fully placed with qualified investors in the amount of 1,541,244 shares (equivalent to 10 per cent of the current share capital). The share capital will therefore be increased by issuing 1,541,244 new no-par value bearer shares from currently 15,419,512 Euros to then 16,960,756 Euros. The gross proceeds amount to approximately € 15.7 million.
Therapeutic area: Cancer - Oncology
